Signaturefd LLC Has $120,000 Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Signaturefd LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 51.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,048 shares of the company’s stock after buying an additional 358 shares during the quarter. Signaturefd LLC’s holdings in Vaxcyte were worth $120,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PCVX. Darwin Global Management Ltd. increased its position in Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after buying an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. increased its position in Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after buying an additional 1,284,883 shares during the last quarter. Capital Research Global Investors increased its position in Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after buying an additional 700,414 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in shares of Vaxcyte in the first quarter valued at about $39,278,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vaxcyte

In related news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.27, for a total transaction of $546,350.00. Following the transaction, the senior vice president now owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 92,098 shares of company stock worth $9,937,773 in the last quarter. Corporate insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Bank of America raised their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. BTIG Research lifted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC lifted their price objective on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho lifted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Finally, Leerink Partners boosted their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $112.80 on Tuesday. The firm has a fifty day moving average of $106.76 and a two-hundred day moving average of $84.80. The stock has a market capitalization of $12.59 billion, a price-to-earnings ratio of -24.10 and a beta of 0.99. Vaxcyte, Inc. has a 52 week low of $46.16 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.